Research Article
Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer
Table 2
Clinical information of unresectable secondary liver cancer patients (n = 18).
| | Characteristics | Statistics |
| | Sex (male/female) | 12/6 | | Age (≥65 years old/<65 years old) | 10/8 | | Medical history | | | Hepatitis (yes/no) | 0/18 | | Alcohol (yes/no) | 1/17 | | Liver cirrhosis (yes/no) | 0/18 | | Tumor diameter (≥50 mm/<50 mm) | 5/13 | | Tumor number | 2.12 ± 1.18 | | Portal vein invasion (yes/no) | 0/18 | | ECOG (0/1/2) | 1/16/1 | | Child–Pugh(A/B) | 18/0 | | Primary lesion | | | Colorectal cancer | 8 | | Gastric cancer | 5 | | Esophagus cancer | 1 | | Pancreatic neuroendocrine tumor | 1 | | Bile duct cancer | 1 | | Lung cancer | 2 | | Treatment history | | | Conventional TACE (yes/no) | 4/14 | | Surgery (yes/no) | 11/7 | | Ablation (yes/no) | 5/13 | | TKI drugs (yes/no) | 7/11 |
|
|
ECOG: Eastern Cooperative Oncology Group; TACE: transarterial chemoembolization; TKI: tyrosine kinase inhibitor.
|
